March 28, 2022
George Goldsmith is President, CEO and Co-Founder of COMPASS Pathways (NASDAQ: CMPS).
Mr. Goldsmith’s initial training and experience was a multidisciplinary blend of cognitive psychology, clinical psychology and computer science. His first company, The Human Interface Group, pioneered collaborative software and was acquired by Lotus Development.
Mr. Goldsmith led the Lotus Institute and developed software and services to support high performance distributed teamwork. He then created TomorrowLab, which provided strategic advice to Internet companies in the late 1990s.
At the same time, he became a senior advisor to the management of McKinsey & Company and eventually joined McKinsey as CEO of [email protected]
Subsequently, as a member of the Young Presidents Organization (YPO) and its International Board of Directors, Mr. Goldsmith founded YPO Networks.
In 2002, he founded Tapestry Networks, an organization committed to improving leadership performance and governance effectiveness in regulated industries.
He is still the non-executive chairman of Tapestry Networks.
In this 3,683-word interview, exclusively in the Wall Street Transcript, George Goldsmith, CEO of COMPASS Pathways PLC (NASDAQ: CMPS) details his company’s development of psilocybin magic mushrooms as an investment.
“So we are working with a very interesting substance called psilocybin and developing a psychedelic drug.
Psilocybin is an active ingredient in what are often called magic mushrooms. What we have developed is a synthetic form, so no fungus is harmed in our work!
Our psilocybin, COMP360, is a synthetic pill developed to the highest standards of pharmaceutical development. We have FDA Breakthrough Therapy designation. So we are developing this as a drug.
But what’s really different is that it’s not just a drug. It is a model of care, with people being carefully supported by specially trained therapists who are present during this powerful psychedelic experience.
And what we’re seeing with that is that it gives people a chance to see their life differently, to have less negativity in the way they see their life and the way they perceive events, and also d less of that kind of rumination and that kind of constant inner voice.
You know, “Gee, maybe it won’t work out well…and if I go into this, will it really work for me…I’ve had this really hard life and I’m just gonna keep having the tough life.”
We know people like that where there’s just this inner voice of expectation. And what our psilocybin therapy seems to do is people see their world in a more positive way, disconnecting them from some of that negativity, and also having less of that inner voice constantly speaking. things, but really taking a more positive and current view of their lives.
Get all the details on the development of psilocybin magic mushrooms in this publicly traded company by reading the entire 3,683 word interview, with George Goldsmith, CEO of COMPASS Pathways PLC (NASDAQ: CMPS) exclusively in the Wall Street Transcript.